content_image/161775.jpg content_image/161774.jpg
## Americas 

We will accelerate oncology franchise growth and strengthen our solid business platform in urology. 

<img src='content_image/161775.jpg'>

<img src='content_image/161774.jpg'>

Fiscal 2013 Overview *Sales and year-on-year changes are based on J-GAAP. Net sales in the Americas amounted to US$2,878 million, up 14.6% from the previous year on a U.S. dollar basis. When converted to yen, with the impact of foreign exchange rates and other factors, net sales grew 38.2% to ¥288.5 billion. 

By product, we posted US$450 million in sales of XTANDI, launched in September 2012, and US$145 million for Myrbetriq, launched a month later in October 2012. Both of these products contributed to the higher overall sales in the Americas. In addition, sales of VESIcare continued to grow, up 2.9% to US$580 million. Our share of the total prescription market for OAB treatments, including VESIcare and Myrbetriq, expanded further. Also, revenues from anticancer drug Tarceva increased. However, sales of Prograf fell due partly to the impact of generics. At the same time, on a U.S. dollar basis overall sales of the pharmacologic stress agents Adenoscan and Lexiscan declined, due mainly to the impact of generics on Adenoscan, despite expanding sales of Lexiscan. 

Fiscal 2014 Outlook *Sales and year-on-year changes are based on IFRS. We forecast regional sales of US$2,892 million, a year-on-year increase of 1.0% on a U.S. dollar basis. When converted to yen, the regional sales are expected to grow 0.8% to ¥289.2 billion. In addition to XTANDI, sales of the OAB treatments VESIcare and Myrbetriq and revenues from Tarceva are forecast to continue growing. On the other hand, we anticipate a decrease in sales of Prograf and overall sales of the pharmacologic stress agents Adenoscan and Lexiscan, mainly due to the impact of generics. 

